Loading...
XNASINVA
Market cap1.08bUSD
Jan 10, Last price  
17.28USD
1D
-0.17%
1Q
-12.73%
Jan 2017
61.50%
Name

Innoviva Inc

Chart & Performance

D1W1MN
XNAS:INVA chart
P/E
6.02
P/S
3.48
EPS
2.87
Div Yield, %
0.00%
Shrs. gr., 5y
-5.19%
Rev. gr., 5y
3.53%
Revenues
310m
-6.30%
8,940,00012,054,00019,587,00022,002,00023,096,00024,374,00024,223,00024,512,000135,758,0004,758,0008,433,00053,949,000133,569,000217,217,000261,004,000261,016,000336,794,000391,866,000331,339,000310,463,000
Net income
180m
-15.99%
-102,654,000-143,164,000-166,044,000-159,997,000-93,643,000-85,302,000-83,862,000-115,344,000-18,542,000-170,701,000-168,464,000-18,760,00059,536,000134,143,000395,056,000157,288,000224,402,000368,837,000213,921,000179,722,000
CFO
141m
-30.07%
-47,823,000-58,645,000-104,791,000-104,372,000-99,911,000-58,064,000-75,144,000-88,338,000-127,954,000-129,602,000-130,723,00010,131,00060,984,000141,748,000223,531,000257,458,000313,113,000363,813,000201,726,000141,064,000
Dividend
Sep 08, 20150.25 USD/sh
Earnings
Feb 26, 2025

Profile

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
URL
https://www.inva.com/
IPO date
Oct 05, 2004
Employees
101
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
310,463
-6.30%
331,339
-15.45%
Cost of revenue
83,320
118,763
Unusual Expense (Income)
NOPBT
227,143
212,576
NOPBT Margin
73.16%
64.16%
Operating Taxes
14,376
66,687
Tax Rate
6.33%
31.37%
NOPAT
212,767
145,889
Net income
179,722
-15.99%
213,921
-42.00%
Dividends
Dividend yield
Proceeds from repurchase of equity
(75,635)
(8,215)
BB yield
5.43%
1.81%
Debt
Debt current
1,207
97,509
Long-term debt
450,711
544,065
Deferred revenue
Other long-term liabilities
81,986
80,790
Net debt
(302,573)
(52,488)
Cash flow
Cash from operating activities
141,064
201,726
CAPEX
(411)
(67)
Cash from investing activities
(66,761)
(56,634)
Cash from financing activities
(171,839)
(55,568)
FCF
298,849
37,717
Balance
Cash
193,513
291,049
Long term investments
560,978
403,013
Excess cash
738,968
677,495
Stockholders' equity
(24,556)
(204,219)
Invested Capital
1,230,573
1,488,525
ROIC
15.65%
10.60%
ROCE
18.83%
16.48%
EV
Common stock shares outstanding
86,876
34,294
Price
16.04
21.06%
13.25
-23.19%
Market cap
1,393,491
206.67%
454,397
-72.07%
EV
1,090,918
401,909
EBITDA
262,848
232,088
EV/EBITDA
4.15
1.73
Interest
19,157
15,789
Interest/NOPBT
8.43%
7.43%